B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Product Manager, Global Medical Affairs Business Insights & Technology: Scientific Content & Public… - Global Medical Affairs BI&T, Scientific Content & Publications

Full-TimePosted on 8/6/2026Deadline 10/30/26
$166.6k - $201.9k+ Discretionary incentive cash + Stock opportunities
Senior, Expert
Bachelor's, MBA
Princeton, NJ, USA
In Person
ProductProduct Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree is required; an MBA is strongly preferred.
  • Strong domain expertise applying Business Insights & Technology to Medical Affairs, including a broad understanding of relevant Medical business capabilities such as Publications and Scientific Content Management, and how technology solutions and data enable them.
  • Seven to ten years of experience in similar Pharmaceuticals IT roles for Medical Affairs or Commercial functions.
  • A track record of leading analysis of complex and ambiguous business needs and integrating them into compelling, actionable strategic plans and investment business cases with global reach.
  • Experience driving digital capabilities to create a superior customer experience.
  • Demonstrated commitment to assessing and applying innovative artificial intelligence and new technologies to Medical Affairs use cases, balancing pragmatic value with transformation.
  • Experience with large-scale application deployments and working with software and consulting partners to ensure maximum value and effectiveness.
  • Experience maximizing value from enterprise Business Insights & Technology platforms, including Veeva Vault MedComms and iEnvision.
  • Working knowledge of agile methodologies applied to the software development lifecycle and IT services.
  • Ability to drive strategic connections between Medical Affairs, Commercial, and Clinical Development functions with an enterprise mindset and reimagine digital capabilities.
  • Ability to influence teams toward an executable vision.
  • Seasoned line- and matrix-management skills, particularly energizing and developing experienced IT professionals across multiple functions.
  • Demonstrated ability to create and support a dynamic culture of innovation and continuous improvement in line reports and in the matrix.
  • A network of external advisors and resources.
Responsibilities
  • Own the technology roadmap by driving development of realistic, actionable multi-year strategic digital capability roadmaps, jointly aligned with business process owners and analytics counterparts; prioritize the portfolio, remain accountable for overall portfolio execution, and understand the data that informs and is generated by business processes.
  • Lead prioritization and development of clear business cases for digital capability investments aligned with the roadmap and platform strategy; define, measure, and achieve business outcomes for high-value, cost-effective capabilities.
  • Maintain awareness of external drivers and relevant technology trends in the product domain and bring forward new ideas.
  • Translate business needs into specific business requirements, identify where technology can competitively differentiate Medical Affairs and add value, and apply a pragmatic fit-for-purpose approach.
  • Build partnerships with senior Medical Affairs leaders to plan and deliver digital capabilities, safeguard digital assets, and support strategic goals.
  • Influence senior business leaders' strategic thinking and help incorporate future digital capabilities into their planning.
  • Build and manage effective business partnerships at all levels during project execution, participate in key business activities and forums, and take accountability for delivering the value proposition of Business Insights & Technology.
  • Partner with business process owners and change-management leads to support effective adoption, including release and cutover planning, impact assessment inputs, communications and training enablement, and hypercare and support readiness; deliver required technical artifacts and inputs on time.
  • Leverage internal Business Insights & Technology partners, including Core Services, Content Capabilities, and Data Capabilities and Analytics, to deliver services to Medical Affairs.
  • Understand accountabilities across the portfolio lifecycle, gather stakeholder requirements, relay them to delivery teams, and own outcomes; build partnerships with delivery team members, application owners, Cybersecurity, and IT Quality Assurance.
  • Ensure delivery teams make appropriate trade-offs among speed, quality, and cost; connect business stakeholders with broader Business Insights & Technology services and capture value throughout the investment lifecycle, from launch through retirement.
  • Communicate successes and issues accurately, urgently, and to the appropriate audience, and manage expectations with business leaders.
  • Address roadblocks to value delivery with urgency and respect.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8

INACTIVE